S&P 500   4,594.62
DOW   34,899.34
QQQ   391.20
S&P 500   4,594.62
DOW   34,899.34
QQQ   391.20
S&P 500   4,594.62
DOW   34,899.34
QQQ   391.20
S&P 500   4,594.62
DOW   34,899.34
QQQ   391.20

AxoGen Stock Forecast, Price & News

-0.84 (-8.05%)
(As of 11/26/2021 12:00 AM ET)
Today's Range
50-Day Range
52-Week Range
256,436 shs
Average Volume
209,475 shs
Market Capitalization
$398.59 million
P/E Ratio
Dividend Yield
30 days | 90 days | 365 days | Advanced Chart
Receive AXGN News and Ratings via Email

Sign-up to receive the latest news and ratings for AxoGen and its competitors with MarketBeat's FREE daily newsletter.

AxoGen logo

About AxoGen

AxoGen, Inc. engages in the development and market of surgical solutions for peripheral nerve regeneration and repair. It also provides products and education to improve surgical treatment algorithms for peripheral nerve damage or discontinuity. The firm's products include avance nerve graft, axoguard nerve connector, axoguard nerve protector, avive soft tissue membrane, acroval neurosensory and motor testing system, and axotouch two-point discriminator. The company was founded in 1977 and is headquartered in Alachua, FL.


AxoGen (NASDAQ:AXGN) Reaches New 52-Week Low at $12.55
November 12, 2021 |  americanbankingnews.com
AxoGen (NASDAQ:AXGN) Sets New 12-Month Low at $12.55
November 5, 2021 |  americanbankingnews.com
AxoGen (NASDAQ:AXGN) Posts Earnings Results
November 4, 2021 |  americanbankingnews.com
AxoGen (NASDAQ:AXGN) Shares Gap Down to $15.60
November 4, 2021 |  americanbankingnews.com
AxoGen's (AXGN) "Buy" Rating Reiterated at JMP Securities
November 4, 2021 |  americanbankingnews.com
AxoGen, inc (AXGN) Q3 2021 Earnings Call Transcript
November 4, 2021 |  finance.yahoo.com
See More Headlines

Industry, Sector and Symbol

Electromedical equipment
Current Symbol
Year Founded

Sales & Book Value

Annual Sales
$112.30 million
Book Value
$2.77 per share


Net Income
$-23.79 million
Pretax Margin




Free Float
Market Cap
$398.59 million

Company Calendar

Last Earnings
Fiscal Year End
Next Earnings (Estimated)


Overall MarketRank

2.09 out of 5 stars

Medical Sector

493rd out of 1,391 stocks

Electromedical Equipment Industry

10th out of 30 stocks

Analyst Opinion: 3.4Community Rank: 4.8Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.6 5 -4 -3 -2 -1 -

AxoGen (NASDAQ:AXGN) Frequently Asked Questions

Is AxoGen a buy right now?

4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for AxoGen in the last year. There are currently 1 hold rating and 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" AxoGen stock.
View analyst ratings for AxoGen
or view top-rated stocks.

How has AxoGen's stock been impacted by Coronavirus?

AxoGen's stock was trading at $10.70 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, AXGN stock has decreased by 10.4% and is now trading at $9.59.
View which stocks have been most impacted by COVID-19

Are investors shorting AxoGen?

AxoGen saw a drop in short interest in the month of November. As of November 15th, there was short interest totaling 499,200 shares, a drop of 44.0% from the October 31st total of 890,800 shares. Based on an average daily trading volume, of 191,000 shares, the days-to-cover ratio is presently 2.6 days. Currently, 1.3% of the shares of the stock are short sold.
View AxoGen's Short Interest

When is AxoGen's next earnings date?

AxoGen is scheduled to release its next quarterly earnings announcement on Monday, February 28th 2022.
View our earnings forecast for AxoGen

How were AxoGen's earnings last quarter?

AxoGen, Inc. (NASDAQ:AXGN) announced its quarterly earnings data on Tuesday, November, 2nd. The medical equipment provider reported ($0.09) EPS for the quarter, topping analysts' consensus estimates of ($0.14) by $0.05. The medical equipment provider had revenue of $31.20 million for the quarter, compared to the consensus estimate of $34.65 million. AxoGen had a negative net margin of 21.59% and a negative trailing twelve-month return on equity of 21.68%. During the same period in the prior year, the firm earned ($0.04) earnings per share.
View AxoGen's earnings history

What guidance has AxoGen issued on next quarter's earnings?

AxoGen issued an update on its FY 2021 earnings guidance on Wednesday, November, 17th. The company provided EPS guidance of for the period. The company issued revenue guidance of $127 million-$129 million, compared to the consensus revenue estimate of $135.29 million.

What price target have analysts set for AXGN?

4 analysts have issued 1 year target prices for AxoGen's stock. Their forecasts range from $20.00 to $27.00. On average, they expect AxoGen's share price to reach $23.50 in the next twelve months. This suggests a possible upside of 145.0% from the stock's current price.
View analysts' price targets for AxoGen
or view top-rated stocks among Wall Street analysts.

Who are AxoGen's key executives?

AxoGen's management team includes the following people:
  • Karen L. Zaderej, Chairman, President & Chief Executive Officer (LinkedIn Profile)
  • Mike Donovan, Vice President-Operations
  • Peter J. Mariani, Chief Financial Officer & Executive Vice President
  • Erick Wayne DeVinney, Vice President-Clinical & Translational Sciences
  • Ivica Ducic, Medical Director

What is Karen Zaderej's approval rating as AxoGen's CEO?

3 employees have rated AxoGen CEO Karen Zaderej on Glassdoor.com. Karen Zaderej has an approval rating of 100% among AxoGen's employees. This puts Karen Zaderej in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of AxoGen own?

Based on aggregate information from My MarketBeat watchlists, some companies that other AxoGen investors own include Advanced Micro Devices (AMD), Bank of America (BAC), Intelsat (I), Intel (INTC), Micron Technology (MU), Xilinx (XLNX), Corbus Pharmaceuticals (CRBP), Exelixis (EXEL), NVIDIA (NVDA) and Fossil Group (FOSL).

What is AxoGen's stock symbol?

AxoGen trades on the NASDAQ under the ticker symbol "AXGN."

Who are AxoGen's major shareholders?

AxoGen's stock is owned by many different retail and institutional investors. Top institutional investors include ArrowMark Colorado Holdings LLC (13.20%), BlackRock Inc. (7.07%), Janus Henderson Group PLC (3.14%), William Blair Investment Management LLC (2.93%), Baillie Gifford & Co. (2.81%) and Point72 Asset Management L.P. (2.71%). Company insiders that own AxoGen stock include Angelo Scopelianos, Erick Wayne Devinney, Gregory Gene Freitag, Isabelle Billet, Karen L Zaderej, Karen L Zaderej, Maria D Martinez, Michael Patrick Donovan and Peter J Mariani.
View institutional ownership trends for AxoGen

Which major investors are selling AxoGen stock?

AXGN stock was sold by a variety of institutional investors in the last quarter, including William Blair Investment Management LLC, Balyasny Asset Management LLC, Assenagon Asset Management S.A., Point72 Asset Management L.P., Millennium Management LLC, Two Sigma Advisers LP, Parkman Healthcare Partners LLC, and Dimensional Fund Advisors LP. Company insiders that have sold AxoGen company stock in the last year include Angelo Scopelianos, Erick Wayne Devinney, Gregory Gene Freitag, Isabelle Billet, Karen L Zaderej, Maria D Martinez, Michael Patrick Donovan, and Peter J Mariani.
View insider buying and selling activity for AxoGen
or view top insider-selling stocks.

Which major investors are buying AxoGen stock?

AXGN stock was acquired by a variety of institutional investors in the last quarter, including ArrowMark Colorado Holdings LLC, American Century Companies Inc., Citadel Advisors LLC, Crestline Management LP, Rice Hall James & Associates LLC, Bamco Inc. NY, BlackRock Inc., and Exchange Traded Concepts LLC.
View insider buying and selling activity for AxoGen
or or view top insider-buying stocks.

How do I buy shares of AxoGen?

Shares of AXGN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is AxoGen's stock price today?

One share of AXGN stock can currently be purchased for approximately $9.59.

How much money does AxoGen make?

AxoGen has a market capitalization of $398.59 million and generates $112.30 million in revenue each year. The medical equipment provider earns $-23.79 million in net income (profit) each year or ($0.67) on an earnings per share basis.

How many employees does AxoGen have?

AxoGen employs 357 workers across the globe.

What is AxoGen's official website?

The official website for AxoGen is www.axogeninc.com.

Where are AxoGen's headquarters?

How can I contact AxoGen?

AxoGen's mailing address is 13631 PROGRESS BLVD. SUITE 400, ALACHUA FL, 32615. The medical equipment provider can be reached via phone at (386) 462-6800, via email at [email protected], or via fax at 386-462-6801.

This page was last updated on 11/28/2021 by MarketBeat.com Staff


Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.